Allakos Reaches Corporate Endpoint with Concentra Acquisition

The independent journey of Allakos as a publicly traded biopharmaceutical firm has concluded following its acquisition by Concentra Biosciences. Shareholders received a final distribution of $0.33 per share, a figure that stands in stark contrast to the stock’s 52-week peak of $1.55. Announced in April 2025, the transaction was finalized by mid-May, with approximately 81% of outstanding shares tendered at the agreed price.

Leadership and Operational Overhaul

The merger precipitated immediate executive changes. Dr. Robert Alexander stepped down from his role as Chief Executive Officer, accompanied by the departure of Chief Financial Officer Baird Radford. Management authority transferred entirely to Concentra’s leadership team. This transition marks the definitive end for investors:

• Trading Ceased: ALLK shares have been delisted from public exchanges
• Final Payout: A disbursement of $0.33 per common share
• Corporate Status: Allakos no longer operates as an independent entity

Remaining developmental assets and pipeline programs will now be managed under the Concentra Biosciences corporate structure.

Clinical Failures Precipitate Decline

The company’s downfall was triggered by severe clinical setbacks. In late January 2025, Allakos announced disappointing trial outcomes for its therapeutic candidate AK006. A Phase 1 study investigating the treatment for chronic urticaria failed to demonstrate clinical efficacy, despite the drug showing acceptable tolerability.

Should investors sell immediately? Or is it worth buying Allakos?

This clinical failure resulted in the immediate termination of the AK006 development program and initiated a drastic corporate restructuring. The company implemented a 75% workforce reduction, shrinking its employee base to approximately 15 staff members.

This recent failure followed earlier developmental troubles. In January 2024, the company had already discontinued its previous lead candidate, lirentelimab (AK002), following two unsuccessful Phase 2 trials. That earlier setback had prompted an initial 50% reduction in personnel.

The acquisition finalizes the story of a biotechnology enterprise that, despite early scientific promise, ultimately could not translate its research into clinical success.